

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jinxin Fertility Group Limited

錦欣生殖醫療集團有限公司*

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 1951)

VOLUNTARY ANNOUNCEMENT

BUSINESS UPDATE ON THE PROPOSED DEVELOPMENT OF A WOMEN'S HEALTH-FOCUSED TRANSLATIONAL MEDICINE PLATFORM

This announcement is made by Jinxin Fertility Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Group's business development.

FURTHER DEVELOPMENT OF THE GROUP'S TRANSLATIONAL MEDICINE CAPABILITIES

The Company is pleased to announce that, building upon its established clinical and reproductive medicine capabilities, the Group intends to further develop a translational medicine platform focused principally on women's health (the “**Platform**”). The Platform will draw upon the Group's existing innovation centre, genetic testing centre, affiliated research platforms, clinical network and reproductive medicine expertise, with a view of advancing the translation of research outcomes into clinical applications.

The Platform is intended to connect unmet clinical needs and patient cohorts with scientific research, disease models, preclinical evaluation, clinical research and, where appropriate, clinical translation. Initial areas of focus are expected to include ovarian ageing, diminished ovarian function and other reproductive and women's health conditions. The Platform remains at an early stage and represents an extension of the Group's existing capabilities; assisted reproductive and related medical services will remain the Group's core business.

RECENT COOPERATION ARRANGEMENTS

The Company is pleased to further announce that, in connection with the Platform, the Group has entered into external cooperation arrangements as set out below.

A. Research Cooperation Memorandum with Professor Ji

The Group recently entered into a research cooperation memorandum with Professor Ji Weizhi (季維智教授)(“**Professor Ji**”), pursuant to which the parties agreed to explore cooperation in reproductive and developmental biology, regenerative medicine, disease models and translational medicine. Initial areas of interest include ovarian ageing, diminished ovarian function and other reproductive and women’s health conditions. Where scientifically justified, non-human primate models may be considered as part of specific research projects. Any specific project will be subject to further scientific evaluation and compliance with applicable laws and regulations.

Professor Ji is an Academician of the Chinese Academy of Sciences, President of the Chinese Society for Stem Cell Research and Dean and Distinguished Professor of the Institute of Primate Translational Medicine at Kunming University of Science and Technology. He has extensive experience in reproductive and developmental biology, regenerative medicine and non-human primate disease models.

B. Framework Cooperation Agreement relating to Research Animal Resources and Reproductive Capabilities

The Group recently entered into a framework cooperation agreement with a cooperation partner possessing relevant research animal resources and breeding capabilities. Pursuant to the agreement, the parties agreed to explore cooperation relating to research animal resources, reproductive breeding capabilities and the development of research cohorts suitable for biomedical research.

The proposed cooperation will explore whether the Group’s assisted reproductive technologies and reproductive medicine expertise may contribute to reproductive management, breeding efficiency and related preclinical research infrastructure, subject to applicable laws and regulations and the entering into of further project-specific arrangements where appropriate.

To the best of the knowledge, information and belief of the directors of the Company, having made all reasonable enquiries, each of the cooperation partners under the agreements above is a third party independent of the Company and its connected persons.

BUILDING AN INTEGRATED TRANSLATIONAL MEDICINE NETWORK

Taken together, the Group’s existing resources and the above cooperation arrangements are intended to form an integrated pathway linking its clinical network and patient resources, innovation centre, genetic testing centre and affiliated research platforms with external scientific, preclinical and clinical research capabilities.

Unmet Clinical Needs and Patient Cohorts → Clinical Data and Biomarkers → Scientific Research → Disease Models and Preclinical Evaluation → Clinical Research → Clinical Translation

Through this model, the Group aims to participate more broadly in the incubation, validation and clinical translation of selected innovative medicines, diagnostics and treatments, and to broaden access to clinical research opportunities. The Platform will be developed prudently on a project-by-project basis, relying mainly on existing facilities, network and research and development resources and external collaborations, without capital-intensive infrastructure development at the current stage.

The Platform and the above arrangements remain at an early stage. The arrangements are general frameworks and do not commit the Group to any specific research, clinical or commercial project or material capital expenditure. Any project will be subject to further assessment, definitive agreements and applicable regulatory and ethical approvals. There is no assurance that any project will proceed to clinical development or commercialisation, and no material impact on the Group's revenue, profit or cash flow is currently expected in the near term. The Company will make further announcements in accordance with the applicable requirements under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited as and when appropriate.

By order of the Board
Jinxin Fertility Group Limited
Dong Yang
*Chief Executive Officer,
Acting Chief Financial Officer
and Executive Director*

Hong Kong, September 9, 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Dong Yang, Dr. Lyu Rong and Dr. Geng Lihong, as executive directors; Mr. Zhong Yong, as chairman and non-executive director, and Ms. Hu Zhe, Ms. Yan Xiaoqing and Mr. Chen Shuyun, as non-executive directors; and Dr. Chong Yat Keung, Dr. Li Jianwei, Mr. Wang Xiaobo and Mr. Ye Changqing, as independent non-executive directors.

* *For identification purposes only*